🇺🇸 Magnesium isoglycyrrhizinate in United States

571 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Platelet Count Decreased — 72 reports (12.61%)
  2. White Blood Cell Count Decreased — 71 reports (12.43%)
  3. Hepatic Function Abnormal — 65 reports (11.38%)
  4. Anaemia — 63 reports (11.03%)
  5. Neutrophil Count Decreased — 58 reports (10.16%)
  6. Pneumonia — 52 reports (9.11%)
  7. Lymphocyte Count Decreased — 51 reports (8.93%)
  8. Alanine Aminotransferase Increased — 48 reports (8.41%)
  9. Off Label Use — 46 reports (8.06%)
  10. Aspartate Aminotransferase Increased — 45 reports (7.88%)

Source database →

Magnesium isoglycyrrhizinate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Magnesium isoglycyrrhizinate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Magnesium isoglycyrrhizinate in United States?

General Hospital of Shenyang Military Region is the originator. The local marketing authorisation holder may differ — check the official source linked above.